9 results
8-K
EX-99.2
NGNE
Neurogene Inc
4 Mar 24
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett
7:30am
Process Control Development Flexibility to manufacture AAV product at low cost Own product quality and development timelines Quality Process development
8-K
EX-99.2
NGNE
Neurogene Inc
5 Jan 24
Neurogene Announces Business Update and 2024 Outlook
7:11am
Process Development Quality Assurance Quality Control Analytical Development Flexibility to manufacture AAV product at low cost Own product quality
8-K
EX-99.4
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
capabilities enable control of product quality and development timelines, strategic pipeline and financial flexibility, as well as clinical-to-commercial
S-4/A
plpjs ku6s72licb
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4
m932h
18 Aug 23
Registration of securities issued in business combination transactions
6:19pm
425
fwavf
18 Jul 23
Business combination disclosure
4:02pm
- Prev
- 1
- Next